Vassilev L - Search Results

1

Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.

Patterson DM, Gao D, Trahan DN, Johnson BA, Ludwig A, Barbieri E, Chen Z, Diaz-Miron J, Vassilev L, Shohet JM, Kim ES. Patterson DM, et al. Among authors: vassilev l. Angiogenesis. 2011 Sep;14(3):255-66. doi: 10.1007/s10456-011-9210-8. Epub 2011 Apr 12. Angiogenesis. 2011. PMID: 21484514

2

MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.

Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T, Ruvolo V, Tsao T, Zeng Z, Vassilev LT, Andreeff M. Kojima K, et al. Blood. 2005 Nov 1;106(9):3150-9. doi: 10.1182/blood-2005-02-0553. Epub 2005 Jul 12. Blood. 2005. PMID: 16014563 Free PMC article.

3

Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML.

Carter BZ, Mak DH, Schober WD, Koller E, Pinilla C, Vassilev LT, Reed JC, Andreeff M. Carter BZ, et al. Blood. 2010 Jan 14;115(2):306-14. doi: 10.1182/blood-2009-03-212563. Epub 2009 Nov 6. Blood. 2010. PMID: 19897582 Free PMC article.

4

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.

Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, Myklebost O, Heimbrook DC, Vassilev LT. Tovar C, et al. Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1888-93. doi: 10.1073/pnas.0507493103. Epub 2006 Jan 27. Proc Natl Acad Sci U S A. 2006. PMID: 16443686 Free PMC article.

5

MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer.

Tovar C, Higgins B, Kolinsky K, Xia M, Packman K, Heimbrook DC, Vassilev LT. Tovar C, et al. Mol Cancer. 2011 May 3;10:49. doi: 10.1186/1476-4598-10-49. Mol Cancer. 2011. PMID: 21539745 Free PMC article.

6

Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.

Carter BZ, Mak DH, Schober WD, Dietrich MF, Pinilla C, Vassilev LT, Reed JC, Andreeff M. Carter BZ, et al. Blood. 2008 Apr 1;111(7):3742-50. doi: 10.1182/blood-2007-05-091504. Epub 2008 Jan 10. Blood. 2008. PMID: 18187663 Free PMC article.

7

Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma.

Ohnstad HO, Castro R, Sun J, Heintz KM, Vassilev LT, Bjerkehagen B, Kresse SH, Meza-Zepeda LA, Myklebost O. Ohnstad HO, et al. Cancer. 2013 Mar 1;119(5):1013-22. doi: 10.1002/cncr.27837. Epub 2012 Nov 16. Cancer. 2013. PMID: 23165797 Free article.

8

Small-molecule inhibitors of the p53-MDM2 interaction.

Vu BT, Vassilev L. Vu BT, et al. Among authors: vassilev l. Curr Top Microbiol Immunol. 2011;348:151-72. doi: 10.1007/82_2010_110. Curr Top Microbiol Immunol. 2011. PMID: 21046355 Review.

9

MDM2 inhibitors for cancer therapy.

Vassilev LT. Vassilev LT. Trends Mol Med. 2007 Jan;13(1):23-31. doi: 10.1016/j.molmed.2006.11.002. Epub 2006 Nov 28. Trends Mol Med. 2007. PMID: 17126603 Review.

10

MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines.

Ohnstad HO, Paulsen EB, Noordhuis P, Berg M, Lothe RA, Vassilev LT, Myklebost O. Ohnstad HO, et al. BMC Cancer. 2011 May 30;11:211:1-11. doi: 10.1186/1471-2407-11-211. BMC Cancer. 2011. PMID: 21624110 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

104 results

Search Page

Filters